Can-Fite BioPharma

CANF · Nasdaq · Israel

Share price · CANF

$1.51-1.94 (-56.23%) 3M

close as of 2026-11-18 · 24h delayed · vol 37K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CANF's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026+9.9%
  2. 2 Sep 2026-28.3%
  3. 2 Jul 2026-15.6%
  4. 1 Jul 2026+55.9%
  5. 26 Jun 2026-6.5%
  6. 9 Jun 2026-5.5%
  7. 4 May 2026+13.3%
  8. 5 Mar 2026-23.6%
  9. 4 Mar 2026+20.4%
  10. 7 Jan 2026+18.3%

Share of unusual movement by asset

For each asset, the share of CANF's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Namodenoson
events and moves
3433%
Piclidenoson
events and moves
136%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—39%

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Adenosine A3 receptor
MASH / NASHHepatocellular Carcinoma
Phase 3
Adenosine A3 receptorSmall molecule
Psoriasis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
August 2027 (1)
PiclidenosonPhase 2Lowe Syndrome
Est. primary completion 2027-08-31 · NCT07410455 · CT.gov ↗
What to watch
December 2027 (1)
PiclidenosonPhase 3Plaque Psoriasis
Est. primary completion 2027-12 · NCT06643260 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2026Topline resultNamodenosonNamodenoson Phase 2a pancreatic cancer data announced

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.4M$6.7M$8.5M$9.8Mreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.7M$5.8M$4.8M+ <$0.1M short-term inv.$2.0M-$7.6M operating cash flowreport ↗
2023-FY$0.7M$6.0M$4.3M+ <$0.1M short-term inv.$1.9M-$8.4M operating cash flowreport ↗
2022-FY$0.8M$7.8M$3.0M+ <$0.1M short-term inv.$2.5M-$11M operating cash flowreport ↗
2021-FY$0.8M$9.8M$4.4M+ $0.2M short-term inv.$3.2M-$9.9M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-04Fishman Pnina · director, Chief Scientific OfficerAward / grant (derivative)24,000——Form 4
2026-06-04Farbstein Motti · CEO, CFO and COOAward / grant (derivative)24,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 0.1M shares ($329K).

#InstitutionSharesValue
1SABBY MANAGEMENT, LLC42,559$132K
2CITADEL ADVISORS LLC34,150$106K
3RHUMBLINE ADVISERS20,908$65K
4CITIGROUP INC5,482$17K
5UBS Group AG2,152$7K
6OSAIC HOLDINGS, INC.450$1K
7FIFTH THIRD BANCORP150$465
8WELLS FARGO & COMPANY/MN125$388
9HRT FINANCIAL LP19,383$60
10Virtu Financial LLC12,908$40
11Activest Wealth Management10$31
12MORGAN STANLEY1$3
13TD Waterhouse Canada Inc.1$3
14Avion Wealth5$0